150 related articles for article (PubMed ID: 1166858)
1. The prognostic and therapeutic implications of DNA:anti-DNA immune complexes in systemic lupus erythematosus (SLE).
Bardana EJ; Harbeck RJ; Hoffman AA; Pirofsky B; Carr RI
Am J Med; 1975 Oct; 59(4):515-22. PubMed ID: 1166858
[TBL] [Abstract][Full Text] [Related]
2. Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus.
Davis P; Cumming RH; Verrier-Jones J
Clin Exp Immunol; 1977 May; 28(2):226-32. PubMed ID: 301447
[TBL] [Abstract][Full Text] [Related]
3. Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody.
Cameron JS; Lessof MH; Ogg CS; Williams BD; Williams DG
Clin Exp Immunol; 1976 Sep; 25(3):418-27. PubMed ID: 1085678
[TBL] [Abstract][Full Text] [Related]
4. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
5. Determination of circulating immune complexes, C3 and C4 complement components and anti-DNA antibody in different classes of lupus nephritis.
Klein MH; Thorner PS; Yoon SJ; Poucell S; Baumal R
Int J Pediatr Nephrol; 1984 Jun; 5(2):75-82. PubMed ID: 6333404
[TBL] [Abstract][Full Text] [Related]
6. Localization of fluorescein-labeled antinucleoside antibodies in glomeruli of patients with active systemic lupus erythematosus nephritis.
Andres GA; Accinni L; Beiser SM; Christian CL; Cinotti GA; Erlanger BF; Hsu KC; Seegal BC
J Clin Invest; 1970 Nov; 49(11):2106-18. PubMed ID: 4097660
[TBL] [Abstract][Full Text] [Related]
7. Correlation between the levels of antinuclear antibodies, anti-DNA antibodies, and complement in systemic lupus erythematosus.
Nguyen CP; Cao VV; Fehér J; Gergely P
Acta Med Hung; 1988; 45(2):145-59. PubMed ID: 3266790
[TBL] [Abstract][Full Text] [Related]
8. The significance of serial measurements of serum complement C3 and C4 components and DNA binding capacity in patients with lupus nephritis.
Garin EH; Donnelly WH; Shulman ST; Fernandez R; Finton C; Williams RL; Richard GA
Clin Nephrol; 1979 Oct; 12(4):148-55. PubMed ID: 315852
[TBL] [Abstract][Full Text] [Related]
9. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).
Lloyd W; Schur PH
Medicine (Baltimore); 1981 May; 60(3):208-17. PubMed ID: 7231154
[TBL] [Abstract][Full Text] [Related]
10. Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus.
Abrass CK; Nies KM; Louie JS; Border WA; Glassock RJ
Arthritis Rheum; 1980 Mar; 23(3):273-82. PubMed ID: 6987992
[TBL] [Abstract][Full Text] [Related]
11. Systemic lupus erythematosus glomerulonephritis in children.
Garin EH; Shulman ST; Donnelly WH; Richard GA
Paediatrician; 1981; 10(5-6):351-67. PubMed ID: 6460214
[TBL] [Abstract][Full Text] [Related]
12. Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus.
Charlesworth JA; Peake PW; Golding J; Mackie JD; Pussell BA; Timmermans V; Wakefield D
Ann Rheum Dis; 1989 Feb; 48(2):153-9. PubMed ID: 2784659
[TBL] [Abstract][Full Text] [Related]
13. Relationship between antibodies to dsDNA and to soluble cellular antigens and histologically defined glomerulonephritis in patients with SLE.
Asero R; Banfi G; Radelli L; Origgi L; Bertetti E; Vanoli M; Riboldi P
Autoimmunity; 1990; 7(1):13-21. PubMed ID: 2103306
[TBL] [Abstract][Full Text] [Related]
14. The significance of serial measurement of serum anti-native DNA antibodies and complement C3 and C4 components in the management of patients with systemic lupus erythematosus.
Grennan DM; Moseley A; Sloane D; Pumphrey R; Dick WC; Buchanan WW
Aust N Z J Med; 1977 Dec; 7(6):625-9. PubMed ID: 306817
[TBL] [Abstract][Full Text] [Related]
15. Immunochemical characteristics of antibodies to DNA in patients with active systemic lupus erythematosus.
Ballou SP; Kushner I
Clin Exp Immunol; 1979 Jul; 37(1):58-67. PubMed ID: 385188
[TBL] [Abstract][Full Text] [Related]
16. DNA-anti-DNA circulating complexes in the nephritis of systemic lupus erythematosus.
Adu D; Dobson J; Williams DG
Clin Exp Immunol; 1981 Mar; 43(3):605-14. PubMed ID: 6974627
[TBL] [Abstract][Full Text] [Related]
17. Clinical studies on the significance of DNA:anti-DNA complexes in the systemic circulation and cerebrospinal fluid (CSF) of patients with systemic lupus erythematosus.
Carr RI; Harbeck RJ; Hoffman AA; Pirofsky B; Bardana EJ
J Rheumatol; 1975 Jun; 2(2):184-93. PubMed ID: 807729
[TBL] [Abstract][Full Text] [Related]
18. Useful laboratory measurements in the management of systemic lupus erythematosus.
Morrow WJ; Isenberg DA; Todd-Pokropek A; Parry HF; Snaith ML
Q J Med; 1982; 51(202):125-38. PubMed ID: 6981121
[TBL] [Abstract][Full Text] [Related]
19. A longitudinal study of high and low avidity antibodies to double-stranded DNA in systemic lupus erythematosus.
McGrath H; Biundo JJ
Arthritis Rheum; 1985 Apr; 28(4):425-30. PubMed ID: 3885960
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal study of circulating immune complexes, dna antibodies and complement in patients with systemic lupus erythematosus: an analysis of their relationship to disease activity.
Harkiss GD; Hazleman BL; Brown DL
J Clin Lab Immunol; 1979 Nov; 2(4):275-83. PubMed ID: 537024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
